CONTENTS
A.
B.
C.
D.
E.
II.
A.
B.
V.
eee
ee 8
© © ©
© 0 6
tee ee ee ee ee we ee ew)
ee we we et ww wh ww tlw tl
© © © © © © © © © @ ew te ew tt
@ © ew we eo ew tw et te et
Background . .
The Accident .
2.
.
1
2.
6
6
©
2
6
6
ee
2 6
ee
© 8
ew
we
ee oe
ew wt
ww
ww
ee
ee
ww
we we
.
2.
2.
6
6
2
6
ee
ew
we
we
we
ew
6
1
1
0
ee
ew
ee
we
we
6
©
©
«©
we
1.
2.
Early Radiation
Residual Radiation . 1...
Data Evaluation
.
2.
....
6 ew ew ew ew
2.
©
©»
ee
we
th
we ee
wt
we ee
ww
te
ew
a
Background . 2. 2. 6 6 ee
ew
ee
1.
2
Methods
. 2. 1. 6 6 0 6 ee
Results and Discussion . 2.
Background .
Methods
. 2.
Results
2. 2.
Discussion.
AGING,
.
2.
2
.
1
6
6
6
2
2
..
.
ww eh we
ew tw ww te eh
we
2. 6
ew
6
ee ww et
6 ee ee ew
et wh
ew wt
2.
2
1
we
©
7 6 6 © ee we ew
we ew we ew we
ew we ew we we
soe we
©
©
ee
eo
ee
ee
ee
ee
ee
ee
ww
we we
et
16
16
16
18
26
re
32
he ee ee
32
te
ee
10
11
26
26
28
28
Chromosome and Genetic Studies . .. 1... 6 ee ee te ew ee eee
l.
Chromosome Studies .....
ye ee
ee ee ew
2.
Isoleucine Misincorporation inn Hemoglobin A of Marshallese o
3.
Detection of Mutant Proteins...
oo
.
.
eee
1. 2. 1. ee ee
GE
te
ee
te
ee
C.
. .
we
we
wt
we
Aging Studies
Immunological Studies
6
we
wt
tw
ww we we we we ee ee
we we ww ew we
wee we wt ww wt
a ee
IMMUNOLOGICAL, " CHROMOSOME, " AND " CENETIC "STUDIES
2...
te
we we
A.
ee
32
33
33
33
35
PARASITOLOGIC SURVEYS AND SUPPRESSIVE ANTI- HELMINTH TREATMENT ON
A.
Background . .
1977-1979
.
2.
1.
1
1
0
2
ew
we
we
1. 2 1 6 0 ee wee ee ew we we
te
we
te
we
te ee te
ee
36
wt
36
B.
C.
D.
Methods
. 2. 2. 6 2 6 ee ew ew
Results and Discussion . . 1. 1
Conclusions
. . 6. 6 1 ew ee
DIABETES SURVEY
. 2...
NEOPLASIA (NON-THYROID)
1
.
6
2.
ew we ee we ww
6 ee ew we ee
ee te he wh ww we
et
et
ew
wh
te ew
hh he
36
38
41
A.
Malignancies
2...
6
ee
ww
ee
ee
te
ee
we
te
te
47
C.
Pituitary Tumor
.
1.
1
1
we
ew
ee
ee
ee
ew
et
ht
te
we
49
.
.
1...
1
2
we
ee
ew
ee
et
wt
et
B.
IX.
ht
th wt
Background . 2. 2 6 6 6 6 ee ww we ee ee we ew te
Methods
. . 2. 2 2 2 oe 6 ee ew ww ew we we ww wt wt we
l.
Procedures . 2. 6. 6 6 2 6 © ee eo ew ww we we we tw wt we
2.
Control Populations
. . 2. 6 6 2 2 ee ee we ew ee we el
Results
.....
a
RONGELAP AND UTIRIK,
VII.
VIII.
6
6
Early Clinical Effects . 2. 2. 6 ee ee ee ww ee ee ee ee
Dosimetric Evaluation . 2. 2. 2. 6 2 6 ee ee te we te we ee
GROWTH AND DEVELOPMENT
A.
B.
C.
D.
B.
VI.
ee
6 8
2. 6
2 6
HEMATOLOGIC OBSERVATIONS
A.
B.
C.
IV.
6
0
2.
6
GENERAL MEDICAL SURVEYS
C.
III.
6
«©
.
2.
re
MOOMnAINIUNW WN ee K
I.
DEDICATION . . 0.
PREFACE
. 2. 6 6
ACKNOWLEDGMENTS
INTRODUCTION . 2.
Benign Tumors
.
. 2.
THYROID ABNORMALITIES
A.
we
1. 6
we
ee
ee
ew
ee
te wt
ee
1. 0. 6 6 1 ew ee we ew
we
Background (Chronology of Developments)
- xii -
tt
et
wt
we
et
we th te
ete we we
ew ee ee
tt wt ee
.... 5.6.1 se
eee
43
47
48
53
53